ArticleFrontiers in immunology2026
Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease, affects more than 30% of the adult population worldwide. Lifestyle interventions and management of metabolic comorbidities are the current main treatments. Thus, it is urgent to find candidate drugs for NAFLD. Traditional Chinese medicine (TCM) formulas have been extensively applied to treat NAFLD in China. Tao-Hong-Si-Wu-Tang (THSWT), a classic TCM formula with anti-oxidation, anti-inflammation, and anti-apoptosis, has emerged as an important formula for hepatoprotection. Based on its biological actions, we speculate that THSWT may have the therapeutic effect on NAFLD. Methods: For dose exploration, the rats were randomly divided into six groups (n = 3-4 in each group): a control group, a model group, and four treatment groups receiving different doses of THSWT (0.5 g/kg, 2.5 g/kg, 5.0 g/kg, 7.5 g/kg; gavage). NAFLD rat model was established by feeding a methionine- and choline-deficient (MCD) diet for two weeks. On day 8 of MCD diet feeding, THSWT treatment was initiated and continued for seven days, with tissue collection performed on day 15. The effect of THSWT on MCD diet-induced hepatic steatosis was evaluated by haematoxylin and eosin (H&E) staining and hepatic steatosis grade scores. The best dosage of THSWT was used to further confirm the protection of THSWT on MCD diet-induced hepatic steatosis in rats. Therefore, a new batch of animals was randomly divided into three groups: a control group, a model group, and a THSWT treatment group (n = 7 in each group). The MCD modelling and THSWT treatment protocols were the same as above. H&E, Oil Red O, and Masson's trichrome staining, qPCR for lipid metabolism-related genes, immunoblot for Collagen I and II, and the commercially available kits for hepatic triglycerides (TG) and hydroxyproline (HYP) and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were used to evaluate the effects of THSWT on hepatic steatosis. Furthermore, immunofluorescence staining and immunoblot were performed to examine the key proteins expression and activation involved in the protection of THSWT on NAFLD. Results: THSWT (2.5 g/kg/day) treatment can alleviate MCD diet-induced hepatic steatosis (including slight fibrosis) in rats. Mechanistically, THSWT treatment is associated with diminishing hepatic reactive oxygen species (ROS), 3-nitrotyrosine (3-NT) and malondialdehyde (MDA) levels, while increasing hepatic GSH levels; inhibiting TLR4/9-IKK-NF-κB-TNF-α/IL-1β/IL-18 innate immune signalling; suppressing JNK and Caspase-3 apoptosis signalling, and Caspase-1/11/8-Gasdermin D (GSDMD) and Caspase-3-GSDME pyroptosis signalling in the liver of rats feeding a MCD diet. Conclusions: THSWT alleviated MCD diet-induced hepatic steatosis in rats possibly
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.